心力衰竭(heart failure,HF)是全球心血管疾病死亡率增加的原因之一,目前对HF的发病机制仍未完全了解,现阶段临床上对HF的治疗只能采取延缓发展的策略,需要发现新的治疗靶点。长链非编码RNA H19(long non-coding RNA H19,lncRNA H19)是一种在HF心脏中高度表达的lncRNA,被视为HF新的治疗靶点,可参与多种心血管疾病的病理生理过程。心力衰竭可由多种疾病(心肌肥大、心肌细胞凋亡、心脏纤维化、心肌缺血再灌注损伤、心肌细胞炎症)发展而来。而lncRNA H19可通过作用于微RNA(microRNA,miRNA)、蛋白质来控制以上疾病的发展。因此深入研究lncRNA H19在不同类型心血管疾病中的作用有助于为心力衰竭的治疗提供新的思路。

Heart failure (HF) is one of the leading causes of increasing mortality associated with cardiovascular diseases worldwide. The pathogenesis of HF remains incompletely understood, and current clinical management focuses on delaying disease progression, highlighting the need for novel therapeutic targets. Long non-coding RNA (lncRNA) H19 is a highly expressed lncRNA in the failing heart, which has emerged as a promising therapeutic target for HF and can participate in the pathophysiological processes of various cardiovascular diseases. Heart failure can develop from a variety of diseases, including myocardial hypertrophy, cardiomyocyte apoptosis, cardiac fibrosis, myocardial ischemia-reperfusion injury, and cardiomyocyte inflammation. lncRNA H19 has been indicated to regulate the development of these diseases by acting on microRNAs (miRNAs) and proteins. Therefore, in-depth study of the role of lncRNA H19 in different types of cardiovascular diseases may provide new insights for the treatment of heart failure.